Edoxaban Antithrombotic Therapy in Diabetic Patients with Atrial Fibrillation and Stable Coronary Artery Disease: The EPIC-CAD Trial

Clicks: 13
ID: 327445
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #130 of 136 articles by views in EP Europace

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 136 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims The appropriate antithrombotic regimen for diabetic patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) who are at high atherothrombotic risk remains uncertain. We evaluated whether the effects of different antithrombotic strategies differ according to diabetes status. Methods and Results The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) was a randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with AF and stable CAD. The primary outcome was a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant nonmajor bleeding at 12 months. Among 1040 randomized patients, 421 (40.5%) had diabetes. There were no differences in the incidence of the primary outcome between diabetic and non-diabetic patients (9.7% vs. 11.6%; hazard ratio [HR] 0.82; 95% confidence interval [CI] 0.56-1.20; P=0.30). The incidence of the primary outcome at 12 months was significantly lower with edoxaban monotherapy than with dual antithrombotic therapy in both diabetic (6.3% vs. 13.7%; HR 0.44; 95% CI 0.23-0.83; P=0.01) and non-diabetic patients (6.7% vs. 16.3%; HR 0.39; 95% CI 0.23-0.65; P=0.001), with no significant interaction between diabetic status and randomized treatment strategy (P-for-interaction=0.78). Conclusions The risk of primary outcome was similar between diabetic and non-diabetic patients with AF and CAD. Irrespective of diabetes status, edoxaban monotherapy led to a lower risk of a primary outcome at 12 months than dual antithrombotic therapy.
Reference Key
openalex_W7207607549 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors S C Lee, Min Soo Cho, Do‐Yoon Kang, Jung-Min Ahn, Jung-Bok Lee, Han-Su Park, Soo Yeon An, Seong-Bong Wee, Kyeong-Won Seo, Yong‐Seog Oh, Chang Hoon Lee, Hyun‐Jung Lee, Ji Hyun Lee, Chang Hee Kwon, Gyung‐Min Park, Hyung Oh Choi, Kyoung‐Ha Park, Kyoung‐Min Park, Jongmin Hwang, Ki‐Dong Yoo, Young–Rak Cho, Ji-Hyun Kim, Ki Won Hwang, Eun‐Sun Jin, Osung Kwon, Ki‐Hun Kim, Seung‐Jung Park, Gi‐Byoung Nam, Duk‐Woo Park
Are you one of these authors? Claim your profile
Journal EP Europace
Year 2026
DOI
10.1093/europace/euag247
URL
https://doi.org/10.1093/europace/euag247
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.